Kenvue Inc. Common Stock

Kenvue Inc. Common Stock Stock Forecast & Price Prediction

Live Kenvue Inc. Common Stock Stock (KVUE) Price
$22.50

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$22.50

P/E Ratio

39.25

Volume Traded Today

$16.7M

Dividend

$0.205

52 Week High/low

23.57/17.67

Kenvue Inc. Common Stock Market Cap

$42.85B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $KVUE ๐Ÿ›‘

Before you buy KVUE you'll want to see this list of ten stocks that have huge potential. Want to see if KVUE made the cut? Enter your email below

KVUE Summary

Based on ratings from 0 stock analysts, the Kenvue Inc. Common Stock stock price is expected to increase by 6.62% in 12 months. This is calculated by using the average 12-month stock price forecast for Kenvue Inc. Common Stock. The lowest target is $21 and the highest is $27. Please note analyst price targets are not guaranteed and could be missed completely.

KVUE Analyst Ratings

Kenvue Inc. Common Stock has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Kenvue Inc. Common Stock will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.

KVUE stock forecast by analyst

These are the latest 20 analyst ratings of KVUE.

Analyst/Firm

Rating

Price Target

Change

Date

Anna Lizzul
B of A Securities

Buy

$27

Maintains

Oct 22, 2024
Andrea Teixeira
JP Morgan

Overweight

$25

Maintains

Oct 11, 2024
Nik Modi
RBC Capital

Sector Perform

$24

Downgrade

Sep 24, 2024
Keith Devas
Jefferies

Buy

$27

Initiates

Sep 24, 2024
Korinne Wolfmeyer
Piper Sandler

Neutral

$21

Maintains

Sep 23, 2024
Nik Modi
RBC Capital

Outperform

$24

Reiterates

Aug 7, 2024
Steve Powers
Deutsche Bank

Buy

$24

Maintains

Aug 7, 2024
Peter Grom
UBS

Neutral

$22

Maintains

Aug 7, 2024
Andrea Teixeira
JP Morgan

Overweight

$24

Maintains

Aug 7, 2024
Steve Powers
Deutsche Bank

Buy

$23

Maintains

Jul 25, 2024
Andrea Teixeira
JP Morgan

Overweight

$22

Maintains

Jul 22, 2024

Citigroup

Neutral


Maintains

Jul 11, 2024
Filippo Falorni
Citigroup

Neutral

$20

Maintains

Jul 10, 2024
Filippo Falorni
Citigroup

Neutral

$21

Reinstates

May 28, 2024
Jeremy Fialko
HSBC

Hold

$21

Maintains

May 8, 2024
Callum Elliott
Bernstein

Underperform

$18

Initiates

Apr 11, 2024
Jon Andersen
William Blair

Market Perform


Initiates

Apr 3, 2024
Bonnie Herzog
Goldman Sachs

Neutral

$20

Maintains

Mar 4, 2024
Bonnie Herzog
Goldman Sachs

Neutral

$20

Downgrade

Mar 1, 2024
Nik Modi
RBC Capital

Outperform

$24

Reiterates

Feb 13, 2024

KVUE Company Information

What They Do: Consumer health products across multiple segments.

Business Model: Kenvue Inc. generates revenue through three main segments: Self Care, Skin Health and Beauty, and Essential Health. Each segment includes a diverse range of well-known products and brands that cater to various consumer health needs, allowing the company to appeal to a broad market.

Other Information: Founded in 2022 and headquartered in Skillman, New Jersey, Kenvue Inc. leverages established brand names like Tylenol, Neutrogena, and Listerine, which provides a strong competitive advantage in the consumer health sector.
KVUE
Kenvue Inc. Common Stock (KVUE)

When did it IPO

2023

Staff Count

22,000

Country

United States

Sector/Industry

Consumer Defensive/Household & Personal Products

CEO

Mr. Thibaut Mongon

Market Cap

$42.85B

Kenvue Inc. Common Stock (KVUE) Financial Data

In 2023, KVUE generated $15.44B in revenue, which was a increase of 3.30% from the previous year. This can be seen as a signal that KVUE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$14.47B

Revenue From 2021

$15.05B

4.06 %
From Previous Year

Revenue From 2022

$14.95B

-0.69 %
From Previous Year

Revenue From 2023

$15.44B

3.30 %
From Previous Year
  • Revenue TTM $15.48B
  • Operating Margin TTM 17.9%
  • Gross profit TTM $8.64B
  • Return on assets TTM 7.0%
  • Return on equity TTM 10.5%
  • Profit Margin 7.2%
  • Book Value Per Share 5.32%
  • Market capitalisation $42.85B
  • Revenue for 2021 $15.05B
  • Revenue for 2022 $14.95B
  • Revenue for 2023 $15.44B
  • EPS this year (TTM) $0.57

Kenvue Inc. Common Stock (KVUE) Latest News

News Image

Mon, 04 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Kenvue (KVUE) is set to report its quarterly performance for September 2024, with key metrics being analyzed beyond Wall Street's estimates.

Why It Matters - Analyzing Kenvue's key metrics offers insights into its financial health and growth potential, influencing investment decisions and stock valuation ahead of quarterly results.

News Image

Wed, 30 Oct 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - The news questions whether minor adjustments can enhance a stock's appeal to investors. Further details on specific changes or stock performance are not provided.

Why It Matters - The mention of "tinkering" suggests potential changes that could enhance the stock's appeal, signaling possible growth or improved performance, affecting investment decisions.

News Image

Thu, 31 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Kenvue Inc. (NYSE: KVUE) announced that Neutrogenaยฎ will form multi-year partnerships with Dr. Dhaval Bhanusali and Dr. Muneeb Shah.

Why It Matters - Kenvue's partnership with influencers could enhance brand visibility and drive sales for Neutrogena, positively impacting revenue and stock performance.

News Image

Sat, 26 Oct 2024

Sentiment - POSITIVE

Source - CNBC

Summary - Starboard Value and Kenvue are reportedly aligned, suggesting favorable conditions for potential value creation.

Why It Matters - Alignment between Starboard Value and Kenvue signals potential strategic initiatives that could enhance profitability and shareholder value, attracting investor interest.

News Image

Sat, 26 Oct 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - An activist investor has acquired a stake in Kenvue stock, indicating potential changes or initiatives to enhance shareholder value.

Why It Matters - An activist investor's stake in Kenvue can drive changes in management strategies, potentially enhancing shareholder value and influencing stock performance.

News Image

Sat, 26 Oct 2024

Sentiment - POSITIVE

Source - The Motley Fool

Summary - Citadel, led by Ken Griffin, has acquired 18 million shares of a lesser-known consumer health stock.

Why It Matters - Ken Griffin's Citadel acquiring 18 million shares signals strong confidence in the consumer health stock, potentially influencing other investors and driving price momentum.

...

KVUE Frequently asked questions

The highest forecasted price for KVUE is $27 from Steve Powers at Deutsche Bank.

The lowest forecasted price for KVUE is $21 from Jeremy Fialko from HSBC

The KVUE analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.